Literature DB >> 16185855

[Lymphocytis meningitis: Listeria monocytogenes is a potential risk in a immunocompetent child].

H Flodrops1, L Houdon, P Gérardin, R Mesnage, A Edmar, S Picot, B Leriche, J Comoy.   

Abstract

UNLABELLED: Meningoencephalitis due to Listeria monocytogenes is a rare and serious form of brainstem infection in childhood. OBSERVATION: We report the case of a 7 year-old girl presenting lymphocytic meningitis with a high CRP level. Parenteral antibiotics combining ceftriaxone and vancomycine led initially to clinical improvement. Ten days later, secondary brainstem inflammation with hydrocephalus appeared and led to the detection of L. monocytogenes during external ventricular bypass.
CONCLUSION: This observation of paediatric lymphocytic meningoencephalitis suggests a prescription of amoxicillin in association with first line antibiotics, particularly when an important inflammatory syndrome exists, immunocompetent children included.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185855     DOI: 10.1016/j.arcped.2005.07.011

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  3 in total

Review 1.  [Listeriosis in adults - case reports and review of the literature].

Authors:  Claudia Metelmann; Katrin Schulz; Rotraud Geldschläger-Canda; Sebastian Plötz; Werner Handrick
Journal:  Wien Klin Wochenschr       Date:  2010-06-23       Impact factor: 1.704

Review 2.  Listeria meningitis and ventriculitis in an immunocompetent child: case report and literature review.

Authors:  S Ben Shimol; M Einhorn; D Greenberg
Journal:  Infection       Date:  2011-08-30       Impact factor: 7.455

3.  Listeria meningitis complicated by hydrocephalus in an immunocompetent child: case report and review of the literature.

Authors:  Giacomo Brisca; Alberto La Valle; Claudia Campanello; Mattia Pacetti; Mariasavina Severino; Giuseppe Losurdo; Antonella Palmieri; Isabella Buffoni; Salvatore Renna
Journal:  Ital J Pediatr       Date:  2020-08-02       Impact factor: 2.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.